AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31381231 — intervention group
Group type: COMPARATOR
Intervention: Oral Methotrexate (MTX)
Number of subjects: 28
Study 31381231 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Methotrexate (MTX)
Number of subjects: 28
Study 28439994 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg once daily, adjustable to 100 or 25 mg as needed)
Number of subjects: 7834
Study 28439994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7834
Study 28439994 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 7834
Study 26028925 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptable sputum specimens for bacterial pneumonia
Number of subjects: 77
Study 26028925 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum with ≥25 white blood cells/low-power field
Number of subjects: 77
Study 23842572 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal tunnel release surgery
Number of subjects: 8
Study 21946445 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal silver and carbossimetyl beta glucan
Number of subjects: 100
Study 21946445 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 100
Study 19775047 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway Supreme (LMAS)
Number of subjects: 70
Study 19775047 — intervention group
Group type: COMPARATOR
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 70
Study 17275886 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 U, subcutaneous injections, once daily until ulcer healing or for a maximum of six months)
Number of subjects: 87
Study 17275886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 15457352 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc slurry (TS) 4 g
Number of subjects: 71
Study 15457352 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin (BL) 60 units
Number of subjects: 71
Study 11037053 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 presurgical immunotherapy (12 million IU/day for 3 days subcutaneously)
Number of subjects: 14
Study 11037053 — intervention group
Group type: COMPARATOR
Intervention: Control group (without IL-2 presurgical immunotherapy)
Number of subjects: 14
Study 9272407 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch renewed on a new skin location
Number of subjects: 20
Study 9272407 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch renewed on the previous application site
Number of subjects: 20
Study 8386652 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: NCI regimen with vinblastine, etoposide, bleomycin and double dose cisplatin (PVeBV) 3 or 4 cycles Q3W
Number of subjects: 115
Study 8386652 — intervention group
Group type: COMPARATOR
Intervention: Arm B: modified PVeBV protocol (bleomycin in continuous infusion) Q4W than a cycle of high-dose E + cyclophosphamide + P2 (PEC) and autologous bone marrow transplantation (ABMT)
Number of subjects: 115
Study 3513504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 26
Study 3513504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 28489694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections
Number of subjects: 133
Study 28489694 — intervention group
Group type: COMPARATOR
Intervention: Observation alone (control group)
Number of subjects: 133
Study 26033153 — intervention group
Group type: EXPERIMENTAL
Intervention: MP‐MRI followed by 10‐ to 12‐core TRUS‐guided random biopsy and cognitive MRI/TRUS fusion targeted biopsy
Number of subjects: 130
Study 26033153 — intervention group
Group type: COMPARATOR
Intervention: TRUS‐guided random biopsy alone
Number of subjects: 130
Study 25700292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25700292 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions in clinical trials
Number of subjects: 0
Study 23878212 — intervention group
Group type: EXPERIMENTAL
Intervention: Claritin advertisements
Number of subjects: 0
Study 23878212 — intervention group
Group type: COMPARATOR
Intervention: Zyrtec advertisements
Number of subjects: 0
Study 20850847 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose insulin (100 pmol/L)
Number of subjects: 24
Study 20850847 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose insulin (400 pmol/L)
Number of subjects: 24
Study 20850847 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (12 mmol/L)
Number of subjects: 24
Study 20850847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide administration (to mimic sepsis)
Number of subjects: 24
Study 20850847 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (5 mmol/L)
Number of subjects: 24
Study 18184849 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MR imaging (fMRI) with verb-generation, phonemic fluency, and semantic fluency tasks
Number of subjects: 20
Study 16849758 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of MGMT expression (97 patients)
Number of subjects: 109
Study 16849758 — intervention group
Group type: COMPARATOR
Intervention: Overexpression of MGMT (12 patients)
Number of subjects: 109
Study 14592280 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP plus modafinil (200 mg/day for week 1; 400 mg/day for weeks 2-4)
Number of subjects: 157
Study 14592280 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP plus modafinil
Number of subjects: 157
Study 14592280 — intervention group
Group type: COMPARATOR
Intervention: nCPAP plus placebo
Number of subjects: 157
Study 10065667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.26 ppm for 2 hours with intermittent exercise)
Number of subjects: 14
Study 10065667 — intervention group
Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 14
Study 7568639 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) reactivity
Number of subjects: 22
Study 7568639 — intervention group
Group type: EXPERIMENTAL
Intervention: LF/HF ratio reactivity
Number of subjects: 22
Study 7568639 — intervention group
Group type: EXPERIMENTAL
Intervention: HF power reactivity
Number of subjects: 22
Study 7568639 — intervention group
Group type: EXPERIMENTAL
Intervention: LF power reactivity
Number of subjects: 22
Study 2023417 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 50 mg/m2 on the 3rd, 10th, and 17th postoperative days
Number of subjects: 135
Study 2023417 — intervention group
Group type: COMPARATOR
Intervention: Control arm (observation only)
Number of subjects: 135
Study 2023417 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 50 mg/m2
Number of subjects: 135
Study 7239459 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterway House program
Number of subjects: 0
Study 7239459 — intervention group
Group type: COMPARATOR
Intervention: Control group (center inpatients)
Number of subjects: 0
Study 31915790 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal ctDCS
Number of subjects: 60
Study 31915790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal ctDCS
Number of subjects: 60
Study 31915790 — intervention group
Group type: COMPARATOR
Intervention: Sham ctDCS
Number of subjects: 60
Study 31434413 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training combined with pelvic floor muscle exercise
Number of subjects: 109
Study 31434413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise
Number of subjects: 109
Study 31434413 — intervention group
Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 109
Study 28765118 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz electroacupuncture (EA) to the trigeminal nerve area
Number of subjects: 16
Study 28765118 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 25828296 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum with 0.6% CPP-ACP for 10 min each day for 1 week before whitening
Number of subjects: 30
Study 25828296 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum without CPP-ACP for 10 min each day for 1 week before whitening
Number of subjects: 30
Study 25828296 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 30
Study 23230283 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN) 0.6 mg/h for 7 days
Number of subjects: 12
Study 23230283 — intervention group
Group type: COMPARATOR
Intervention: Transdermal glyceryl trinitrate (GTN) 0.6 mg/h (acute administration)
Number of subjects: 12
Study 21567343 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified auricular composite grafts
Number of subjects: 70
Study 19029035 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratus OCT
Number of subjects: 104
Study 19029035 — intervention group
Group type: COMPARATOR
Intervention: Cirrus OCT
Number of subjects: 104
Study 17028482 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/benazepril HCl (5/20 mg/d force‐titrated to 5/40 mg/d)
Number of subjects: 70
Study 17028482 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate monotherapy (5 mg/d force‐titrated to 10 mg/d)
Number of subjects: 70
Study 15525618 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Ropivacaine
Number of subjects: 40
Study 15525618 — intervention group
Group type: COMPARATOR
Intervention: 0.2% Levobupivacaine
Number of subjects: 40
Study 12230021 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokishakuyakusan
Number of subjects: 0
Study 9717985 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEMZAR)
Number of subjects: 0
Study 9717985 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil
Number of subjects: 0
Study 7695323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil oral suspension with food
Number of subjects: 20
Study 7695323 — intervention group
Group type: COMPARATOR
Intervention: Cefpodoxime proxetil oral suspension under fasting conditions
Number of subjects: 20
Study 2695815 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 I.U. of salmon calcitonin (sCT) nasal spray daily (n = 20)
Number of subjects: 40
Study 2695815 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 I.U. of sCT by subcutaneous injection every second day (n = 10)
Number of subjects: 40
Study 2695815 — intervention group
Group type: COMPARATOR
Intervention: Oral calcium supplement, 1 g per day (control group, n = 10)
Number of subjects: 40
Study 2695815 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin groups (sCT nasal spray and subcutaneous injection)
Number of subjects: 40
Study 2695815 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 40
Study 334475 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150 mg to 300 mg daily)
Number of subjects: 23
Study 334475 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (75 mg to 150 mg daily)
Number of subjects: 23
Study 6184571 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 160 mg twice daily
Number of subjects: 9
Study 6184571 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg twice daily
Number of subjects: 9
Study 6184571 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 9
Study 6184571 — intervention group
Group type: COMPARATOR
Intervention: Verapamil and Labetalol
Number of subjects: 9
Study 31711858 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized text messages thrice a week
Number of subjects: 248
Study 31711858 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 248
Study 29527974 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 6190
Study 29527974 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 6190
Study 26965639 — intervention group
Group type: EXPERIMENTAL
Intervention: Menu-plus intervention condition
Number of subjects: 8
Study 26965639 — intervention group
Group type: COMPARATOR
Intervention: Menu-only intervention condition
Number of subjects: 8
Study 26965639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sales of healthy children's menu items
Number of subjects: 8
Study 26965639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordering behaviors of dining parties
Number of subjects: 8
Study 24188511 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Focused Therapy (FFT‐CHR)
Number of subjects: 66
Study 24188511 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care (EC)
Number of subjects: 66
Study 22352379 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic coaching applying TTM tailoring for exercise and minimal tailoring for stress management
Number of subjects: 3391
Study 22352379 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet program applying TTM tailoring for stress management and minimal tailoring for exercise
Number of subjects: 3391
Study 22352379 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving assessment only
Number of subjects: 3391
Study 20556928 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily fixed combination latanoprost-timolol
Number of subjects: 44
Study 20556928 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.50% twice daily associated with once daily latanoprost
Number of subjects: 44
Study 20556928 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.50% twice daily (control group)
Number of subjects: 44
Study 16950210 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP) 16 mg/d
Number of subjects: 10
Study 16950210 — intervention group
Group type: COMPARATOR
Intervention: BUP placebo
Number of subjects: 10
Study 15906586 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg once daily
Number of subjects: 1684
Study 15906586 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 1684
Study 15906586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1684
Study 12074403 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA testing in the general population
Number of subjects: 5371
Study 12074403 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels 4-10 ng/ml
Number of subjects: 5371
Study 12074403 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels >10 ng/ml
Number of subjects: 5371
Study 12074403 — intervention group
Group type: COMPARATOR
Intervention: Comparison with prostate cancer screening program
Number of subjects: 5371
Study 10091816 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blocking agents
Number of subjects: 6780
Study 10091816 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blocking agents + Enalapril
Number of subjects: 6780
Study 10091816 — intervention group
Group type: COMPARATOR
Intervention: Control (nonuse of beta-blockers)
Number of subjects: 6780
Study 7822398 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined open and percutaneous repair
Number of subjects: 22
Study 7822398 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 22
Study 2108614 — intervention group
Group type: COMPARATOR
Intervention: UFT 600 mg/body/day (Group C)
Number of subjects: 0
Study 2108614 — intervention group
Group type: COMPARATOR
Intervention: UFT 400 mg/body/day for 12 months (Group D)
Number of subjects: 0
Study 2108614 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (dosage between 8 to less than 12 mg/kg)
Number of subjects: 0
Study 2108614 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (dosage more than 12 mg/kg)
Number of subjects: 0
Study 2108614 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of UFT
Number of subjects: 0
Study 2108614 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued administration of UFT
Number of subjects: 0
Study 155295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (Atrovent) 0.125 mg x 4 daily
Number of subjects: 19
Study 155295 — intervention group
Group type: COMPARATOR
Intervention: Terbutalin (Bricanyl) 5 mg x 4 daily
Number of subjects: 19
Study 30955055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of bladder neck descent (BND) during stress by two operators
Number of subjects: 50
Study 28337029 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein energy restriction (HP-ER, 1.7 g kg-1 per day)
Number of subjects: 22
Study 28337029 — intervention group
Group type: COMPARATOR
Intervention: Normal protein energy restriction (NP-ER, 0.9 g kg-1 per day)
Number of subjects: 22
Study 28337029 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (ER)
Number of subjects: 22
Study 28337029 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein energy restriction (HP-ER)
Number of subjects: 22
Study 25196890 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day
Number of subjects: 24
Study 25196890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23351572 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (GlideScope)
Number of subjects: 60
Study 23351572 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngoscopy (MacIntosh)
Number of subjects: 60
Study 23351572 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (GlideScope) by experienced physicians
Number of subjects: 60
Study 23351572 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (GlideScope) by inexperienced physicians
Number of subjects: 60
Study 21261935 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone group (behavior counseling by phone)
Number of subjects: 276
Study 21261935 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet group (behavior counseling by e‐mail)
Number of subjects: 276
Study 21261935 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 276
Study 19300037 — intervention group
Group type: EXPERIMENTAL
Intervention: Piclozotan
Number of subjects: 158
Study 17376233 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based composite measure of totally controlled (TC) asthma
Number of subjects: 3416
Study 17376233 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based composite measure of well controlled (WC) asthma
Number of subjects: 3416
Study 17376233 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference criteria: Forced expiratory volume in 1 second (FEV1)
Number of subjects: 3416
Study 17376233 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference criteria: Asthma Quality of Life Questionnaire (AQLQ)
Number of subjects: 3416
Study 17376233 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based composite measures (TC and WC)
Number of subjects: 3416
Study 15248820 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (1.7 microg/kg per day)
Number of subjects: 12
Study 15248820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11687541 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin (ET)-1 at 5 ng/kg x min with BQ123 (60 microg/kg x min)
Number of subjects: 24
Study 11687541 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ123 at 60 microg/kg x min
Number of subjects: 24
Study 11687541 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ123 at 120 microg/kg x min
Number of subjects: 24
Study 11687541 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin (ET)-1 at 2.5 ng/kg x min or higher with BQ123
Number of subjects: 24
Study 11687541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9159303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer antigen 125 (CA125) measurement in peritoneal dialysis effluent (PDE)
Number of subjects: 76
Study 9159303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer antigen 125 (CA125) measurement in PDE
Number of subjects: 76
Study 9159303 — intervention group
Group type: EXPERIMENTAL
Intervention: History of peritonitis and duration of CAPD
Number of subjects: 76
Study 9159303 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of hypertonic dialysate in small-volume CAPD (3 x 2 L daily exchange)
Number of subjects: 76
Study 8254063 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (N = 15)
Number of subjects: 30
Study 8254063 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 15)
Number of subjects: 30
Study 3425219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal administration of diazepam
Number of subjects: 0
Study 3425219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal administration of midazolam
Number of subjects: 0
Study 3425219 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular administration of diazepam
Number of subjects: 0
Study 31495010 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Nursing Work Life (QNWL)
Number of subjects: 400
Study 31495010 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Saudi nationality, higher age, more work experience, married status, full-time employment, rotating shift, specialty units
Number of subjects: 400
Study 29165539 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐management Plus intervention (combined self‐management education, physical activity, and health professional support)
Number of subjects: 145
Study 29165539 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 145
Study 29165539 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐management Plus intervention
Number of subjects: 145
Study 25523430 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch with memantine
Number of subjects: 0
Study 25523430 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch alone
Number of subjects: 0
Study 25523430 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.6 mg/24 h rivastigmine patch with memantine
Number of subjects: 0
Study 25523430 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.6 mg/24 h rivastigmine patch alone
Number of subjects: 0
Study 25523430 — intervention group
Group type: COMPARATOR
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 0
Study 25523430 — intervention group
Group type: COMPARATOR
Intervention: 4.6 mg/24 h rivastigmine patch
Number of subjects: 0
Study 23475381 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 32